Research output per year
Research output per year
Project Details
Project Description
NHMRC Practitioner Fellowship (level 1) application - Andrew Wei
| Status | Finished |
|---|---|
| Effective start/end date | 1/01/18 → 31/12/22 |
-
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
Moujalled, D. M., Brown, F. C., Chua, C. C., Dengler, M. A., Pomilio, G., Anstee, N. S., Litalien, V., Thompson, E., Morley, T., MacRaild, S., Tiong, I. S., Morris, R., Dun, K., Zordan, A., Shah, J., Banquet, S., Halilovic, E., Morris, E., Herold, M. J., Lessene, G., & 5 others, 9 Feb 2023, In: Blood. 141, 6, p. 634–644 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access37 Citations (Scopus) -
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Thijssen, R., Diepstraten, S. T., Moujalled, D., Chew, E., Flensburg, C., Shi, M. X., Dengler, M. A., Litalien, V., MacRaild, S., Chen, M., Anstee, N. S., Reljić, B., Gabriel, S. S., Djajawi, T. M., Riffkin, C. D., Aubrey, B. J., Chang, C., Tai, L., Xu, Z., Morley, T., & 16 others, 20 May 2021, In: Blood. 137, 20, p. 2721-2735 15 p.Research output: Contribution to journal › Article › Research › peer-review
80 Citations (Scopus) -
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
Chua, C. C., Roberts, A. W., Reynolds, J., Fong, C. Y., Ting, S. B., Salmon, J. M., MacRaild, S., Ivey, A., Tiong, I. S., Fleming, S., Brown, F. C., Loo, S., Majewski, I. J., Bohlander, S. K. & Wei, A. H., 20 Oct 2020, In: Journal of Clinical Oncology. 38, 30, p. 3506-3517 12 p.Research output: Contribution to journal › Article › Research › peer-review
130 Citations (Scopus)